StocksMedium•28 September 2026•
1 min read
MediciNova Stock Drops as Liver Drug Tipelukast Fails Phase 2 Trial
Key Facts
1MediciNova reported Phase 2 topline trial results for tipelukast in treating NAFLD and hypertriglyceridemia.
2The drug fell short on the liver fat parameter, leading to a tumble in the company's stock price.
MediciNova reported Phase 2 topline trial results for tipelukast in treating non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia. Benzinga reported that the drug fell short on the primary liver fat parameter, leading to a tumble in the company's stock price.
MNOV closed at $2.58 on September 25, 2026, after reaching a session low of $2.53. The downward movement follows investor disappointment over the clinical trial results, which failed to satisfy key efficacy benchmarks for liver fat reduction.